CNTB MEXC RealStocks
Own real CNTB shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-12 13:17:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Connect Biopharma Holdings Limited (CNTB) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.75, with a market capitalization of $42.96M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.68 to $3.82. This page covers its latest market performance, valuation, price trends and company information.
$42.96M | |
$0.69 | |
$0.75 | |
$0.69 | |
$0.69 | |
3.20K | |
4.04M | |
-- | |
$3.82 | |
$0.68 | |
-- | |
-- |
Connect Biopharma Holdings Limited (CNTB) is trading at $0.75 in pre-market trading as of 2026-11-12 13:05:00, up 8.87% ($0.06) from the previous close of $0.69
Pre-market trading shows how investors are pricing CNTB before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Connect Biopharma Holdings Limited (CNTB) moved from $0.77 to $0.75, representing a decline of 3.11% ($0.02).
The stock traded between $0.68 and $0.81 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 311.44 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 2.2%
CNTB is currently trading at $0.75, placing it 2.2% of the way from its 52-week low of $0.68 to its 52-week high of $3.82. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 64 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for Connect Biopharma Holdings Limited.
Dividend | |
|---|---|
| Ex-Dividend Date | -- |
| Payment Date | -- |
| Dividend Per Share | -- |
Stock Split | |
|---|---|
| Split Date | -- |
| Split Ratio | -- |
Eligible investors can buy real shares of Connect Biopharma Holdings Limited (CNTB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to CNTB, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between CNTB shares and USD.
CNTB Shares to USD
1.00 CNTB shares = 0.75 USD
Calculations are estimates based on the latest available price and are for reference only.